Roswell Park Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Roswell Park Cancer Institute sits in the top decile of US sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count).
Roswell Park Cancer Institute: 365 sponsored US clinical trials, 57 recruiting.
Roswell Park Cancer Institute sponsors 365 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 200 completed. 7 of these trials are in Phase 3-4 (later-stage) and 238 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 9 trials.
Top-decile sponsor footprint
Roswell Park Cancer Institute ranks in the top decile of sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
200 of 279 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
365 total, page 6 of 8
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
NCT00675233
Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer
NCT00794989
Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
NCT00625183
Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis
NCT01014598
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
NCT00612560
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
NCT00646139
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
NCT00849186
DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements
NCT00550563
Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
NCT00528775
Vitamin D in Treating Patients With Prostate Cancer
NCT00524680
Breast and Cervical Cancer Educational Intervention for Latinas in Western New York
NCT01760850
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
NCT00524459
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
NCT00524186
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
NCT01682044
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT00524316
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
NCT00470067
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
NCT00470535
Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer
NCT00470184
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer
NCT00537121
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
NCT00470496
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00526890
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
NCT00536991
Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery
NCT00470353
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
NCT00536601
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
NCT00523848
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00524589
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
NCT00524121
Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression
NCT01531881
Effect of a Low Glycemic Index Diet on Breast Density
NCT01237938
Bupropion in Helping Adults Stop Smoking
NCT00534001
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00244985
Fulvestrant in Treating Patients With Advanced Prostate Cancer
NCT00244998
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
NCT00258258
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
NCT00248495
Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis
NCT00524485
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
NCT00217516
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
NCT00084721
Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
NCT00403000
Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00238225
Fentanyl With or Without Bupivacaine in Reducing Pain in Patients Undergoing Video-Assisted Chest Surgery
NCT00538499
Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer
NCT00096330
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00182806
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
NCT00112892
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
NCT00054158
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
NCT00100815
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
NCT00217477
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
NCT00107315
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
NCT00217464
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00096044
Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer
NCT00526461
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 123 |
| Phase 2 | 115 |
| Phase 3 | 5 |
| Phase 4 | 2 |
What is open in the Roswell Park Cancer Institute pipeline
57 recruiting of 365 indexed (16% open); 200 completed (55%).
Phase mix: 7 late (III/IV) vs 238 early (I/II) (early-phase heavy).
Top condition: Leukemia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Roswell Park Cancer Institute: open-pipeline peers nationwide
Peers matched on 365 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Roswell Park Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 365 trials (± recruiting share)
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Cambridge Health Alliance · 16% recruiting · 45 trials
- Louisiana State University Health Sciences Center in New Orleans · 16% recruiting · 45 trials
- University of Southern California · 16% recruiting · 617 trials
- Incyte Corporation · 15% recruiting · 239 trials
Related
What to do with this Roswell Park Cancer Institute page
365 registered trials is a research-attention snapshot, not an endorsement of Roswell Park Cancer Institute or any single study.
- 57 of Roswell Park Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Roswell Park Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Roswell Park Cancer Institute pipeline card: 365 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.